Drug Pricing

Drug Pricing

  • Drug Iceberg 2.0 Published

    In February 2018 the Irish platform for patient organisations, science and industry (IPPOSI) and the Medical Research Charities Group (MRCG) announced the publication of the second “Drug Iceberg” Report. This report lay out key recommendations including a call for the development of a new national strategy on access to medicines. 

     

     

     

  • Statement from Cystic Fibrosis Ireland on New Drug Pricing Deal

    Cystic Fibrosis Ireland broadly welcomes and congratulates the Minister for Health, Simon Harris TD, for the new deal with the Irish Pharmaceutical Healthcare Association (IPHA), which has the potential to make savings of €750 million over the next four years from the existing drugs budget in Ireland.

    We further welcome the Minister’s commitment that this funding will provide greater access to new and innovative therapies, and we hope this will include life-changing drugs for cystic fibrosis. We also know how much this will potentially mean for our colleagues working in cancer, heart and eye conditions, and for rarer diseases such as Muscular Dystrophy, Multiple Sclerosis, Cystinosis, Epidermolysis Bullosa, Huntington's Disease, and many other very challenging adult and childhood diseases.

    We would ask that, as part of the new system, patient group perspectives on new drugs, including quality-of-life issues, are formally factored in to the new multi-tiered system for approving new and innovative drugs, including at Cabinet level.

    Philip Watt, CEO of Cystic Fibrosis Ireland, stated:
    "Congratulations to Minister Harris and IPHA for this new agreement that has the potential to free up €750m funding over the next four years for new and innovative drugs that will benefit many patients in Ireland including those with cystic fibrosis. Ultimately the success of this new system will be judged by the extent of greater access of ill patients to these wonderful new drugs. It is, in general, a very exciting time in terms of clinical trials and drugs 'in the pipeline'."

    ENDS